Protocol Ledger

NCT04388839 · Phase II · ACTIVE NOT RECRUITING

Evolutionary Therapy for Rhabdomyosarcoma

Interventional Phase II clinical trial protocol NCT04388839 sponsored by H. Lee Moffitt Cancer Center and Research Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-29 Enrollment: 12 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04388839
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)12 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04388839
Protocol FieldVerified Registry Value
NCT IdentifierNCT04388839
Consolidated Lead SponsorH. Lee Moffitt Cancer Center and Research Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment12 participants (ACTUAL)
Registered Start Date2020-12-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04388839
Hospital Research SiteLocationSite Profile
Connecticut Children's Medical CenterHartford, CTOpen Hospital Dossier ->
University of FloridaGainesville, FLOpen Hospital Dossier ->
Johns Hopkins All Children's HospitalSaint Petersburg, FLOpen Hospital Dossier ->
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Moffitt Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI